Premium
Evaluation of iron‐chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron‐chelating drug
Author(s) -
Hershko Chaim,
Grady Robert W.,
Link Gabriela
Publication year - 1982
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1982.tb02778.x
Subject(s) - in vivo , chelation , excretion , chemistry , deferoxamine , ethylenediamine , pharmacology , iron status , drug , toxicity , mononuclear phagocyte system , biochemistry , iron deficiency , medicine , inorganic chemistry , immunology , biology , organic chemistry , microbiology and biotechnology , anemia
S ummary . Fifteen compounds with a high affinity to ferric iron have been screened for in vivo iron‐chelating efficiency in a rat model. One of the most potent of these drugs was ethylenediamine‐N,N′‐bis(o‐hydroxyphenylglycine) (EHPG). EHPG‐induced iron excretion was up to 8 times higher than iron excretion induced by identical doses of desferrioxamine (DF). Studies employing selective radio‐iron probes of reticuloendothelial and parenchymal iron stores showed that although EHPG is able to interact with both storage iron compartments, its effect on parenchymal iron is much more pronounced. Unlike DF which has two alternative routes of excretion, EHPG‐induced iron excretion is restricted mainly to the gut. Although EHPG seems to be superior to DF in both its chelating efficiency and preferential interaction with hepatic parenchymal iron stores, information on its in vivo toxicity is at present insufficient and it cannot yet be recommended for clinical use.